Drug Trial Radar · NCT00304616
SWitching to Abilify Trial (SWAT)
Last checked: Nov 20, 2026Latest source record: Dec 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Oct 2004
Primary completion
Jun 2006
Study completion Oct 2007
Sponsor
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
Conditions
- Schizophrenia
Interventions
Aripiprazole, Solian, Olanzapine, Seroquel, RisperidoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- CGI-I mean score(at week 1, 3, 4, 8 & every 4 weeks until week 26)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.